Autopsy report · NCT04458103

Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD

“There were excess adverse events in study population compared to baseline controls”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month after it had already started.
• Ran for about 3 years 1 month before it stopped.
• 161 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Massachusetts General Hospital

Sponsor type

University, hospital or other

Conditions

Heart Failure

Interventions

Percutaneous RVAD

Participants

161

Sites

1

Countries

United States

Trials that died the same way

• Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)
  “investigation of adverse events in a related clinical study” (69% match in meaning)
• Radiation Therapy for Heterotopic Ossification Prophylaxis Acutely After Elbow Trauma
  “there was an unacceptably high adverse event rate in the treatment group.” (63% match in meaning)
• Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
  “Due to adverse events” (61% match in meaning)
• Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
  “Adverse Events” (59% match in meaning)
• Treatment for Alcohol Dependence With Gabapentin
  “Due to poor compliance of patients in the study.” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.